FDA Approves Pegcetacoplan to Reduce Proteinuria in 2 Kidney-Related Diseases
The treatment proved efficacy across all 3 key markers of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
EHA 2025: Golcadomide Shows Deep Responses in High-Risk Follicular Lymphoma
Julio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in…
FDA Restricts Elevidys Use Amidst New Safety Concerns
FDA places clinical hold on Sarepta’s Elevidys gene therapy after safety concerns, but ambulatory patients regain access amid ongoing investigations.
Tildrakizumab Improves Signs, Symptoms of Active Psoriatic Arthritis in Phase 3 Studies
Tildrakizumab 100 mg shows significant efficacy in treating psoriatic arthritis, achieving key clinical trial end points and offering hope for…
High Burden of Pneumococcal Disease Found in Older Adults With Underlying Medical Conditions
Data from a retrospective study of adults in France found the highest incidence of pneumococcal disease in patients with the…
Product News for July 2025
Discover groundbreaking FDA approvals for HIV prevention, targeted treatments, and OTC allergy relief, enhancing patient care and access to essential…
Evolving Business Models in Specialty and Infusion Pharmacy
Hospitals and health systems are adapting specialty and infusion pharmacy strategies to meet evolving payer mandates, rising costs, and shifting…
Meta-Analysis Suggests P2Y12 Inhibitor Is a Better Choice for Long-Term Single Antiplatelet Therapy
A meta-analysis suggests that long-term P2Y12 inhibitor monotherapy after percutaneous coronary intervention may offer superior protection against major adverse cardiac…
FDA Approves Sepiapterin for Adults, Children Living With Phenylketonuria
Sepiapterin treatment allowed for patients to liberalize their diet while reaching or exceeding recommended daily protein allowances in patients living…
EHA 2025: GOLCA Plus Rituximab Shows Promise in R/R DLBCL
Julio C. Chavez, MD, MS, discusses updated data from the European Hematology Association (EHA) 2025 Congress on the investigational oral…